key: cord-0815950-zhciwcut
authors: Cattaneo, Dario; Corbellino, Mario; Clementi, Emilio; Galli, Massimo; Riva, Agostino; Gervasoni, Cristina
title: Does lopinavir really inhibit SARS-CoV-2?
date: 2020-05-11
journal: Pharmacol Res
DOI: 10.1016/j.phrs.2020.104898
sha: 0bf4618d8aea8295bb7d4fbfa9dc33c54971b3db
doc_id: 815950
cord_uid: zhciwcut

nan

HIV protease inhibitors are being considered as potential treatment of COVID-19, the disease caused by Severe Acute Respiratory Syndrome coronavirus-2 (SARS-CoV-2). In particular, the use of lopinavir/ritonavir has been supported by in vitro data, animal studies and clinical data in patients with other coronavirus infections, specifically SARS and Middle East Respiratory Syndrome (reviewed in [1] ). However, early experiences with the use of lopinavir/ritonavir in COVID-19 patients provided conflicting results. Indeed, Ye, et al showed that, compared with treatment of pneumonia-associated adjuvant drugs alone, the association with lopinavir/ritonavir had more favorable effects in lowering the body temperature [2] . Conversely, Cao and co-workers, in a prospective, randomized, open-label trial, reported no added benefit of lopinavir-ritonavir in hospitalized adult patients with severe Covid-19 treated with standard of care [3] . We believe that such findings could have been predicted a priori just looking at available in vitro/in vivo data.

Lopinavir was identified as a potential treatment of SARS in 2003, with a half maximal inhibitory concentration (IC50) of 50 micromolar (M) [4] . More recently the in vitro antiviral effect of lopinavir was tested also against SARS-CoV-2, resulting in an IC50 of 26 µM [5] .

Considering that COVID-19 patients are treated with the same lopinavir/ritonavir doses used for the treatment of HIV (400/100 mg twice daily), we compared the IC50 values found for SARS-CoV and SARS-CoV-2 with those found for the inhibition of HIV. The IC50 of lopinavir/ritonavir for HIV is 0.006 µM, a concentration that is 4000-to-8000 folds lower than those able to inhibit SARS-CoV and SARS-CoV-2 (Table 1) 

So, the key question is: what is the minimum concentration of lopinavir able to effectively inhibit SARS-CoV replication in vivo? To address this issue, three factors need to be considered. Firstly, the IC50 is not the ideal pharmacodynamic parameter because at this concentration 50% of the virus still replicates; therefore, the IC90 should preferably be considered. Accordingly, the lopinavir IC90 values were estimated from IC50 considering a J o u r n a l P r e -p r o o f Hill slope factor of 1 (using https://www.graphpad.com/quickcalcs/Ecanything1.cfm). Secondly, lopinavir, circulates in the body largely bound plasma proteins (>95%) and its inhibitory activity on virus replication relies on the 5% or less free drug fraction. Therefore, the IC values need to be adjusted for serum protein content. Thirdly, drug concentrations at the site of infection should be properly considered. To address these two latter issues, we estimated the lopinavir protein-adjusted IC90 in the lung and the central nervous systems, considering the epithelial lining fluid (ELF)-to-plasma and cerebrospinal fluid (CSF)-to-plasma ratios of 1.7 and 0.004 [7, 8] . We also assumed that lopinavir free fractions in ELF and in CSF were 35% and 100%, respectively, based on the fact that the concentrations of albumin in ELF and CSF are approximately 7-fold and 200-fold lower than plasma [9, 10] .

As shown in Table 1 , the in vitro protein-adjusted IC90 values for HIV, SARS-CoV and SARS-CoV-2 were 1.00, 9000 and 4680 µM in plasma, 0.14, 756 and 393 in ELF, and 12.5, 112500 and 58500 in CSF. Lopinavir plasma concentrations measured in vivo in HIVinfected and in COVID-19 patients ranged from 1 to 20 µM and 10 to 40 µM, respectively [11, 12] .

Considered together, these data clearly indicate that the current dose of lopinavir provides effective concentrations exceeding the protein adjusted IC90 only for HIV. Conversely, the concentrations of lopinavir are 200-fold, 20-fold and 2000-fold lower than the proteinadjusted IC90 values for SARS-CoV-2 inhibition in plasma, ELF, and CSF, respectively. It is, therefore, not surprising that lopinavir was ineffective for the treatment of SARS-CoV-2, as Cao documented. The doses required to provide optimal inhibition are obviously impracticable due to unacceptable risk of toxicity. These limitations need to be carefully considered before to embarking in the planning of large scale, randomized controlled clinical trials including lopinavir-ritonavir as one of the key treatment arms for COVID-19 [13] .

J o u r n a l P r e -p r o o f In vitro, lopinavir PA-IC90, (plasma) M 1.00 9000 4680

In vitro, lopinavir PA-IC90, (ELF) M 0.14 756 393

In vitro, lopinavir PA-IC90, (CSF) M 12.5 112500 58500

In vivo, lopinavir trough, M* 1 -20 Not available 10 -50

Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment

Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019

A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19

Small molecules targeting severe acute respiratory syndrome human coronavirus

Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro

Detection of intrapulmonary concentration of lopinavir in an HIV-infected patient

Cerebrospinal fluid and plasma lopinavir concentrations and viral response in virologically suppressed patients switching to lopinavir/ritonavir monotherapy once daily

Changes in epithelial lining fluid albumin associated with smoking and interstitial lung disease

Correlation between vancomycin penetration into cerebrospinal fluid and protein concentration in cerebrospinal fluid/serum albumin ratio

Is it time to revise antiretrovirals dosing? a pharmacokinetic viewpoint

Lopinavir/ritonavir in Covid-19 patients: maybe yes, but at what dose?

WHO launches global megatrial of the four most promising coronavirus treatments